skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study

Review

(2442) Views  (732) Full article downloads

Authors: JP Baguet, R Asmar, P Valensi, S Nisse-Durgeat, JM Mallion

Published Date January 2009 Volume 2009:5 Pages 175 - 183
DOI: http://dx.doi.org/10.2147/VHRM.S3409

JP Baguet1, R Asmar2, P Valensi3, S Nisse-Durgeat4, JM Mallion1

1Clinique de Cardiologie, CHU de Grenoble, Grenoble, France; 2Institut CardioVasculaire, Paris, France; 3Service d’Endocrinologie-Diabétologie-Nutrition, CHU Jean Verdier, AP-HP, Bondy, France; 4Laboratoires Takeda, Puteaux, France

Abstract: In hypertension and diabetes, early structural changes of the arterial wall precede or support atherosclerosis. There is evidence that some antihypertensive drugs exert an antiatherosclerotic effect. Over 36 months, we investigated the effect of candesartan cilexetil (CC) on the common carotid intima-media thickness (IMT) vs amlodipine besylate (AML) in patients with type 2 diabetes and mild to moderate essential hypertension. After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12.5 mg if necessary. No significant differences were observed between the two groups for change in IMT at M12 (−0.001 vs −0.027 mm/year for CC and AML respectively, p = 0.425), at M24 (−0.033 vs −0.019 mm per year respectively, p = 0.442), and at the last visit (−0.016 vs −0.039 mm per year respectively, p = 0.549). Within the group, comparisons did not show a significant difference in changes in IMT from baseline to the three visits. At the last visit, IMT regression was observed in 52.2% of patients receiving CC and in 51.3% of those receiving AML (p = 0.908). The augmentation in carotid lumen diameter from baseline was statistically greater in the AML group at the last visit (p = 0.034). BP variations during the study were similar in the two groups. The results of this study show that CC and AML treatments may alter identically the natural progression of carotid IMT in hypertensive type 2 diabetic patients.

Keywords: hypertension, diabetes, carotid, intima-media thickness, candesartan, amlodipine






 

Other articles by Professor Jean-Philippe Baguet



Readers of this article also read:

Candesartan cilexetil in the treatment of chronic heart failure
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
ABO and rhesus blood group distribution in Kurds
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
Management of acute attacks of hereditary angioedema: potential role of icatibant
Effectiveness of coordination exercise in improving cognitive function in older adults: a prospective study
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University